Projects per year
Organization profile
Organisation profile
宗旨：
促進本校生技醫藥商品化發展，提供一校三院同仁醫藥品研發服務，以開發具有創新性與前瞻性之生技醫藥產品開發為宗旨。
背景：
生技醫藥為我國重要產業，建立藥品及醫材開發的關鍵價值鏈平台是校園研究成果產業化最大的助力。為有效統整及加速本校之新藥及醫材研發能量，規劃成立臺北醫學大學生技醫藥商品化中心(TMU Biomedical Commercialization Center)，藉由商品化中心跨院系所專業團隊間的整合運作，提供一校三院同仁生技藥品臨床前到IND申請之臨床前研究(pre-clinical study)諮詢與服務。此外，透過北醫事業發展處協助醫藥品商品化開發策略，包含藥物市場定位分析，法規、專利檢索和諮詢服務，技術轉移或尋求業界承接產學合作案，及衍生新創事業體之相關規劃。
目的：
整合新藥開發及醫療器材從臨床前研究到IND/IDE所需之技術發展平台(Research Development)，提供校內外單位委託合作或共同開發之服務。
搭配事業發展處之資源協助擬定生技醫藥品商業化發展策略(Business Development)、專利布局及商業化輔導，以加速產出具有創新性與前瞻性的生技醫藥品。
初期以藥品的商業化平台為目標：規劃由藥物設計/合成與篩選、藥理活性、藥物動力學、藥物代謝、藥效、毒理、小試量產、製劑開發等提供平台服務。
Fingerprint Dive into the research topics where TMU Biomedical Commercialization Center is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Histone Deacetylase Inhibitors
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Cells
Chemical Compounds
Histone Deacetylases
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
Mucocutaneous Lymph Node Syndrome
Medicine & Life Sciences
Tubulin
Medicine & Life Sciences
Tubulin Modulators
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Wei-Chiao Chang
- Department of Clinical Pharmacy
- Master Program for Clinical Pharmacogenomics and Pharmacoproteomics
- Ph.D Program in Biotechnology Research and Development
- TMU Research Center of Cancer Translational Medicine
- TMU Biomedical Commercialization Center
Person: Researcher
Projects 2010 2019
- 135 Finished
開發可一步驟增殖並武裝T細胞之全人化雙功能抗體以進行腫瘤專一性治療(3/3)
8/1/18 → 7/31/19
Project: A - Government Institution › b - Ministry of Science and Technology
乳癌細胞尼古丁受體表現與新穎抗體奈米藥物之臨床前試驗評估-開發抗α9尼古丁受體/抗聚乙二醇雙功能抗體以提升奈米藥物之乳癌標靶療效(2/3)
8/1/18 → 7/31/19
Project: A - Government Institution › b - Ministry of Science and Technology
乳癌細胞尼古丁受體表現與新穎抗體奈米藥物之臨床前試驗評估－開發抗α9尼古丁受體/抗聚乙二醇雙功能抗體以提升奈米藥物之乳癌標靶療效(2/3)(相對補助)
8/1/18 → 7/31/19
Project: A - Government Institution › f - Other (Funded by Government)
Research Output 1996 2019
2
Citations
(Scopus)
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., Jan 15 2019, In : European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.Research output: Contribution to journal › Article
Benzamides
Histone Deacetylases
Tubulin
Heterografts
Inhibitory Concentration 50
Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells
Nepali, K., Lin, M. H., Chao, M. W., Peng, S. J., Hsu, K. C., Eight Lin, T., Chen, M. C., Lai, M. J., Pan, S. L. & Liou, J. P., Oct 1 2019, In : Bioorganic Chemistry. 91, 103119.Research output: Contribution to journal › Article
Growth Inhibitors
Amides
Prostatic Neoplasms
Cells
Lead compounds
2
Citations
(Scopus)
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo
Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.Research output: Contribution to journal › Article
Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation